Sanofi Maintains Growth Streak But Oncology Pipeline Renewal Efforts Stall
With Trial Discontinuation
The French major saw strong Q3 sales and raised its business guidance accordingly, but the discontinuation of an early-stage trial has added to a growing list of setbacks the firm has faced in reviving its oncology pipeline.